KMB Forensic analysis

Trading Setup & Entry Strategy

KMB is currently in a BEARISH_DOWNTREND but trading near the lower Bollinger Band ($95.14), suggesting a potential exhaustion of recent selling pressure. We are adopting a 'Value-Accumulation' approach given the upcoming Kenvue synergy play.

• >Entry Zone: $95.50 - $96.50. Accumulate 50% now at $96.47, add 50% on a test of $95.15 (Bollinger Lower Band).
• >Stop Loss: $92.50 (Hard stop). A breach of this level invalidates the recovery thesis and risks a move toward 2025 lows.
• >Take Profit: $102.50 (Initial target, 50-day SMA), $109.00 (Major resistance/200-day SMA).
• >Risk/Reward: 1:3.3 (Risk $3.97/share, Reward $12.53/share to 200-day SMA).

Material Events & Strategy

The pending Kenvue Acquisition (expected 2H 2026) remains the primary catalyst. While management is aggressively cutting costs via the 2024 Transformation Initiative ($1.5B total cost), the focus on streamlining operations and the upcoming IFP joint venture with Suzano S.A. (approved by the European Commission as of May 12, 2026) suggests a pivot toward higher-margin consumer health focus.

Financial Health & Forensics

• >Revenue Quality: Net sales are stable (+2.7% YoY), though organic growth is pressured by divestitures.
• >Balance Sheet: Debt levels remain elevated ($7.1B total debt vs $1.9B equity), but the company is generating robust cash from operations ($745M in Q1 2026).
• [WARN]Red Flags: High Goodwill/Intangibles and massive restructuring charges ($859M cumulative) indicate high operational risk during the transition period.

Technical Analysis

• >RSI: 46.25 (Neutral). The stock is not oversold, but momentum is clearly negative.
• >Trend: BEARISH_DOWNTREND. Price is currently 11.73% below the 200-day SMA ($109.29).
• >Reconciliation: While fundamentals are improving through M&A, the technical picture is broken. We are playing the 'mean reversion' rather than a 'momentum breakout'.

Short-Term Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Position Size: 3% of portfolio.
• >Max Hold: 10 Days.
• >Catalyst: Market sentiment shifting as the Suzano/IFP transaction clears regulatory hurdles.

One-Liner Thesis: KMB is a classic 'Value-Turnaround' play; the technicals remain weak, but the impending Kenvue merger and successful divestment of the IFP business provide a defined floor at the $95 level.